These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12362222)

  • 1. Cost trends in the treatment for hemophilia: another view.
    Kletter SD; Rankin PJ
    Thromb Haemost; 2002 Oct; 88(4):542-4. PubMed ID: 12362222
    [No Abstract]   [Full Text] [Related]  

  • 2. [The use of coagulation factors in hemophilia treatment].
    Berger K; Schramm W
    Pharm Unserer Zeit; 2006; 35(1):66-73. PubMed ID: 16465868
    [No Abstract]   [Full Text] [Related]  

  • 3. Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations.
    Teitel JM
    Haemophilia; 1999 Sep; 5 Suppl 3():43-9. PubMed ID: 10597387
    [No Abstract]   [Full Text] [Related]  

  • 4. Can costs of hemophilia products be curtailed? Not as we do business today!
    Aledort LM
    Thromb Haemost; 2002 Oct; 88(4):541. PubMed ID: 12362221
    [No Abstract]   [Full Text] [Related]  

  • 5. Hemophilia market awaits next-generation therapies.
    Sheridan C
    Nat Biotechnol; 2011 Nov; 29(11):960. PubMed ID: 22068523
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic aspects of haemophilia care.
    Aldedort LM; Miners A; Bohn R; Borrero P; Goudemand J; Hoots K; Kavakli K; Lee C; Roberts J; Schramm W; Szucs T; Wasserman J
    Haemophilia; 1999 May; 5(3):216-9. PubMed ID: 10484669
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic impact of treating inhibitor patients.
    Lacey L
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():29-32. PubMed ID: 12214144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia.
    Rogoff EG; Guirguis HS; Lipton RA; Seremetis SV; DiMichele DM; Agnew GM; Karpatkin M; Barish RJ; Jones RL; Bianco C; Knothe BD; Lee MS
    Thromb Haemost; 2002 Oct; 88(4):545-53. PubMed ID: 12362223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High cost, low volume care: the case of haemophilia.
    Lee C; Sabin C; Miners A
    BMJ; 1997 Oct; 315(7114):962-3. PubMed ID: 9365285
    [No Abstract]   [Full Text] [Related]  

  • 10. Self-sufficiency--20 years on.
    Schädlich PK
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S9-14. PubMed ID: 7795147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic impact of obesity in severe haemophilia children on clotting factor prophylaxis in a single institution.
    Majumdar S; Ostrenga A; Latzman RD; Payne C; Hunt Q; Morris A; Iyer R
    Haemophilia; 2011 Jul; 17(4):717-8. PubMed ID: 21323798
    [No Abstract]   [Full Text] [Related]  

  • 12. Haemophilia prophylaxis: how can we justify the costs?
    Feldman BM; Berger K; Bohn R; Carcao M; Fischer K; Gringeri A; Hoots K; Mantovani L; Willan AR; Schramm W
    Haemophilia; 2012 Sep; 18(5):680-4. PubMed ID: 22507524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GAO suggests Medicare make separate payments for clotting factors, delivery.
    Young D
    Am J Health Syst Pharm; 2003 Apr; 60(8):741. PubMed ID: 12749159
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemophilia in the managed care setting.
    Dalton DR
    Am J Manag Care; 2015 Mar; 21(6 Suppl):S123-30. PubMed ID: 26168207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The World Federation of Hemophilia's third global forum on the Safety and Supply of Hemophilia Treatment Products, 22-23 September 2003, Budapest, Hungary.
    Brooker M
    Haemophilia; 2004 May; 10(3):290-4. PubMed ID: 15086330
    [No Abstract]   [Full Text] [Related]  

  • 16. Hemophilia centre twinning with Nanfang Hospital, Guangzhou, China. Challenges and opportunities.
    Luke KH
    Transfus Apher Sci; 2001 Oct; 25(2):83-7. PubMed ID: 11761278
    [No Abstract]   [Full Text] [Related]  

  • 17. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
    Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
    Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing hemophilia: safer, more effective but expensive.
    Golden WE; Wells C
    J Ark Med Soc; 2004 Aug; 101(2):50-1. PubMed ID: 15318445
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18-30 years) with hemophilia.
    Witkop M; Guelcher C; Forsyth A; Hawk S; Curtis R; Kelley L; Frick N; Rice M; Rosu G; Cooper DL
    Am J Hematol; 2015 Dec; 90 Suppl 2():S3-10. PubMed ID: 26619194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
    Hay JW; Zhou ZY
    Haemophilia; 2010 Mar; 16(2):366-8; discussion 369-71. PubMed ID: 19811544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.